Trends in Pharmacological Sciences
ReviewLong-circulating (sterically stabilized) liposomes for targeted drug delivery
Abstract
Anticancer chemotherapy is limited by adverse side-effects resulting from toxicities to normal tissues. Targeted delivery of drugs to diseased tissues in vivo would help to reduce these side-effects. Liposomes containing lipid derivatives of polyethylene glycol (sterically stabilized liposomes) have circulation times that are sufficiently long to allow for effective in vivo drug delivery, and are discussed in this review by Theresa Allen. Sterically stabilized liposomes, containing entrapped doxorubicin, targeted to squamous cell lung carcinoma by means of specific antibodies attached at the liposome surface are capable of reducing tumour burden to a significant extent and eradicating tumour in a significant percentage of mice.
References (40)
- G. Gregoriadis
FEBS Lett.
(1973) - T.M. Allen et al.
FEBS Lett.
(1987) - A.L. Klibanov et al.
FEBS Lett.
(1990) - G. Blume et al.
Biochim. Biophys. Acta
(1990) - T.M. Allen et al.
Biochim. Biophys. Acta
(1991) - J. Senior et al.
Biochim. Biophys. Acta
(1991) - D.D. Lasic et al.
Biochim. Biophys. Acta
(1991) - D. Needham et al.
Biochim. Biophys. Acta
(1992) - G. Blume et al.
Biochim. Biophys. Acta
(1993) - T.M. Allen
Adv. Drug Del. Rev.
(1994)
FEBS Lett.
Biochim. Biophys. Acta
Biochim. Biophys. Acta
Biochim. Biophys. Acta
J. Mol. Biol.
Cancer Res.
Cited by (446)
Lipid nanoparticle mRNA systems containing high levels of sphingomyelin engender higher protein expression in hepatic and extra-hepatic tissues
2023, Molecular Therapy Methods and Clinical DevelopmentLipid nanoparticles (LNPs) for delivery of mRNA usually contain ionizable lipid/helper lipid/cholesterol/PEG-lipid in molar ratios of 50:10:38.5:1.5, respectively. These LNPs are rapidly cleared from the circulation following intravenous (i.v.) administration, limiting uptake into other tissues. Here, we investigate the properties of LNP mRNA systems prepared with high levels of “helper” lipids such as 1,2-distearoyl-sn-glycero-3-phosphorylcholine (DSPC) or N-(hexadecanoyl)-sphing-4-enine-1-phosphocholine (egg sphingomyelin [ESM]). We show that LNP mRNAs containing 40 mol % DSPC or ESM have a unique morphology with a small interior “solid” core situated in an aqueous compartment that is bounded by a lipid bilayer. The encapsulated mRNA exhibits enhanced stability in the presence of serum. LNP mRNA systems containing 40 mol % DSPC or ESM exhibit significantly improved transfection properties in vitro compared with systems containing 10 mol % DSPC or ESM. When injected i.v., LNP mRNAs containing 40 mol % ESM exhibit extended circulation lifetimes compared with LNP mRNA systems containing 10 mol % DSPC, resulting in improved accumulation in extrahepatic tissues. Systems containing 40 mol % ESM result in significantly improved gene expression in spleen and bone marrow as well as liver post i.v. injection compared with 10 mol % DSPC LNP mRNAs. We conclude that LNP mRNAs containing high levels of helper lipid provide a new approach for transfecting hepatic and extrahepatic tissues.
Brain gene therapy with Trojan horse lipid nanoparticles
2023, Trends in Molecular MedicineThe COVID-19 mRNA vaccine was developed by the scalable manufacture of lipid nanoparticles (LNPs) that encapsulate mRNA within the lipid. There are many potential applications for this large nucleic acid delivery technology, including the delivery of plasmid DNA for gene therapy. However, gene therapy for the brain requires LNP delivery across the blood–brain barrier (BBB). It is proposed that LNPs could be reformulated for brain delivery by conjugation of receptor-specific monoclonal antibodies (MAbs) to the LNP surface. The MAb acts as a molecular Trojan horse to trigger receptor-mediated transcytosis (RMT) of the LNP across the BBB and subsequent localization to the nucleus for transcription of the therapeutic gene. Trojan horse LNPs could enable new approaches to gene therapy of the brain.
Cancer is a second leading disease-causing death worldwide that will continuously grow as much as 70% in the next 20 years. Chemotherapy is still becoming a choice for cancer treatment despite its severity of side effects and low success rate due to ineffective delivery of the chemodrugs. Since it was introduced in 1960, significant progress has been achieved in the use of liposomes in drug delivery. The study aims to review relevant literatures on role of PEGylated liposome in enhancing cytotoxic activity of several agents. A systematic literature on the use of PEGylated liposomes in anticancer research via Scopus, Google scholar and PubMed databases was conducted for studies published from 2000 to 2022. A total of 15 articles were selected and reviewed from 312 articles identified covering a variety of anticancer treatments by using PEGylated liposomes. PEGylated liposome which is purposed to achieve steric equilibrium is one of enhanced strategies to deliver anticancer drugs. It has been shown that some improvement of delivery and protection form a harsh gastric environment of several anticancer drugs when they are formulated in a PEGylated liposome. One of the successful drugs that has been clinically used is Doxil®, followed by some other drugs in the pipeline Various drugs (compounds) had been used to enhance the efficacy of PEGylated liposomes for targeted cancer cells in vitro and in vivo. In conclusion, PEGylated liposomes enhance drug activities and have great potential to become efficient anticancer delivery to follow Doxil® in the clinical setting.
Comprehensive review on novel targets and emerging therapeutic modalities for pulmonary arterial Hypertension
2022, International Journal of PharmaceuticsPulmonary Arterial Hypertension (PAH) is the progressive increase in mean pulmonary arterial pressure (mPAP) (≥20 mmHg at rest). Current treatment strategies include the drugs targeting at nitric oxide pathway, endothelin receptors, prostaglandin receptors, thromboxane receptors and phosphodiesterase inhibitors, which provides the symptomatic relief. Despite of these treatments, the mortality amongst the PAH patients remains high due to non-reversal of the condition. This review primarily covers the introduction of PAH and the current treatments of the disease. This is followed by the newer disease targets expressed in the pathobiology of the disease like Rho Kinase Pathway, Vasoactive Intestinal Peptide Pathway, Receptor Tyrosine Kinases, Serotonin signalling pathway, Voltage-gated potassium (Kv) channel pathway. Newer formulation strategies for targeting at these specific receptors were covered and includes nano formulations like liposomes, Micelles, Polymeric Nanoparticles, Solid Lipid Nanoparticles (SLN), Bioresorbable stents, NONOates, Cell-Based Therapies, miRNA therapy for PAH. Novel targets were identified for their role in the pathogenesis of the PAH and needs to be targeted with new molecules or existing molecules effectively. Nanosystems have shown their potential as alternative carriers on the virtue of their better performance than traditional drug delivery systems.
Stimuli-responsive phospholipid-drug conjugates (PDCs)-based nanovesicles for drug delivery and theranostics
2020, International Journal of PharmaceuticsLiposomes represent one of the most successful nano-drug delivery systems among enormous nano-carriers. Although great progress has been made in conventional liposomes, the emerging shortcomings still impair the therapeutic index. The proposal of stimuli-responsive phospholipid-drug conjugates (PDCs)-based nanovesicles solves the challenges that conventional liposomes are faced with, showing great potential for cancer diagnosis and therapy. Herein, we intend to overview the current progress and unique advantages of stimuli-responsive PDCs-based nanovesicles. First, the challenges of conventional liposomes and the development of PDCs-based nanovesicles are summarized. Next, the stimuli-responsive elements used in current stimuli-responsive PDCs-based nanovesicles are outlined. Then, the unique superiorities of stimuli-responsive PDCs-based nanovesicles for drug delivery and theranostics are highlighted in detail. Finally, the future opportunities and challenges of stimuli-responsive PDCs-based nanovesicles for clinical translation are put forward.
Drug delivery nanosystems for neural regenerative medicine
2020, Neural Regenerative NanomedicineDisorders in the brain and peripheral nervous system cause neurodegenerative diseases. Many of the drugs commonly used in the diagnosis and treatment of neurodegenerative disorders (ND) cannot show their effectiveness because they do not pass the blood–brain barrier (BBB). In order to eliminate this deficiency, many developed drug transport nanosystems to prevent drug degradation and loss, to reduce possible side effects, to increase drug biocompatibility, and to provide controlled drug release to various regions. Different nanocarrier systems, which are an important tool for the safe delivery of effective drugs to the target area, could pass BBB and thus can be used to diagnose and treat ND. Drugs, gene, or therapeutic molecules are transported to the diseased area with different nanocarrier systems. The use of transported active substances to repair damaged areas is an indication of the progression of regenerative medicine in the diagnosis and treatment of diseases.
Regenerative medicine allows to increase the body’s natural abilities for healing to replace the damaged one with a healthy organ and provide the regeneration of diseased tissues by reviving the patient’s own cells or stem cells to the patient by performing certain functions in the laboratory. Regenerative medicine has been used in the treatment of numerous chronic degenerative disorders such as cardiovascular diseases, central nervous system, oncology, diabetes, skin, and orthopedic disorders. In this chapter, the drug delivery nanosystems such as lipid, polymeric, inorganic nanocarriers, and nanofibers and therapeutic applications of them at the neural diseases will be examined. In particular, the drug delivery nanosystems necessary for the treatment of neurodegenerative diseases, the advantages and disadvantages of these systems, the effect of the BBB, and the possible mechanism behind this effect will be described in detail in this section.
With a better understanding of the structure of the BBB and the general characteristics of drug delivery nanosystems, determining the passage of drug delivery systems through this barrier will lead to the development of regenerative therapeutic applications of these systems.